LL-37: The Human Cathelicidin Antimicrobial Peptide — Research Overview

Introduction

LL-37 is the sole member of the cathelicidin family of antimicrobial peptides (AMPs) expressed in humans. Derived from the C-terminal domain of the precursor protein hCAP18 (human cationic antimicrobial protein 18), LL-37 is a 37-amino acid peptide with the sequence beginning with two leucine residues — hence its designation. With a molecular weight of approximately 4493 Daltons and a net positive charge of +6 at physiological pH, LL-37 is amphipathic and adopts an α-helical conformation in membrane-mimicking environments. This structural feature is central to its diverse biological activities observed in experimental models.

Molecular Structure & Mechanism of Antimicrobial Action

LL-37's primary antimicrobial mechanism in experimental models involves membrane disruption. The cationic peptide is electrostatically attracted to the negatively charged bacterial membrane surface. Upon contact, it inserts into the lipid bilayer and disrupts membrane integrity through several proposed models:

- Carpet model: LL-37 accumulates on the membrane surface and disrupts it in a detergent-like manner - Toroidal pore model: Peptide-lipid complexes form transient pores that allow ion leakage - Barrel-stave model: Peptide oligomers insert perpendicularly to form stable transmembrane channels

Research has demonstrated LL-37's activity against a broad spectrum of pathogens in vitro, including Gram-positive bacteria (S. aureus, S. epidermidis), Gram-negative bacteria (E. coli, P. aeruginosa), fungi (Candida albicans), and enveloped viruses [1]. Notably, LL-37 has shown activity against biofilm-forming organisms, disrupting established biofilms and preventing new biofilm formation — a property of significant research interest given the clinical challenge of biofilm-associated infections [2].

Immunomodulatory Functions in Experimental Models

Beyond direct antimicrobial activity, LL-37 functions as a multifunctional immunomodulatory molecule in experimental settings:

Chemokine and Cytokine Modulation: LL-37 has been shown to induce the production of IL-8, MCP-1, and IP-10 in epithelial cells, facilitating the recruitment of neutrophils and monocytes to sites of infection. Paradoxically, it can also suppress LPS-induced TNF-α production in macrophages, demonstrating context-dependent immunomodulation [3].

Dendritic Cell Activation: Research in human dendritic cell models has shown that LL-37 can enhance antigen uptake, promote dendritic cell maturation, and augment T-cell priming. It has been identified as a potent activator of plasmacytoid dendritic cells (pDCs) through the formation of complexes with self-DNA that activate TLR9 [4].

Neutrophil Function: In neutrophil models, LL-37 has been demonstrated to enhance phagocytosis, ROS production, and NET (neutrophil extracellular trap) formation, while also modulating apoptosis to extend neutrophil lifespan at infection sites [5].

Wound Healing Research

LL-37 has attracted considerable research interest for its potential role in wound healing processes. In keratinocyte and fibroblast models, LL-37 has been shown to: - Promote cell migration and proliferation through activation of EGFR (epidermal growth factor receptor) - Stimulate angiogenesis via upregulation of VEGF and FGF2 - Modulate MMP (matrix metalloproteinase) activity to facilitate tissue remodeling - Enhance re-epithelialization in excisional wound models [6]

Oncology Research Applications

Emerging research has revealed a complex, context-dependent role for LL-37 in cancer biology. In some tumor models, LL-37 has demonstrated direct cytotoxic activity against cancer cells through membrane disruption. In others, it has been shown to modulate the tumor microenvironment by influencing immune cell infiltration and cytokine profiles. Research in ovarian cancer, lung cancer, and melanoma models has produced varied results, highlighting the need for further investigation into the context-specific roles of LL-37 in oncology [7].

Research Applications

- Antimicrobial research: Studying membrane disruption mechanisms and broad-spectrum activity - Biofilm disruption studies: Investigating LL-37 as a tool to disrupt established biofilms - Wound healing models: Exploring keratinocyte and fibroblast migration and proliferation - Immunomodulation research: Studying innate immune activation and dendritic cell biology - Cancer immunology: Investigating tumor microenvironment modulation

---

This article is for scientific and educational reference only. All products are for research use only and not for human or animal consumption.

References

1. Mookherjee, N., et al. (2020). Antimicrobial host defence peptides: functions and clinical potential. Nature Reviews Drug Discovery, 19(5), 311–332.
2. Overhage, J., et al. (2008). Human host defense peptide LL-37 prevents bacterial biofilm formation. Infection and Immunity, 76(9), 4176–4182.
3. Vandamme, D., et al. (2012). A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology, 280(1), 22–35.
4. Lande, R., et al. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449(7162), 564–569.
5. Tecle, T., et al. (2007). Cathelicidins. Respiratory Research, 8(1), 1–11.
6. Heilborn, J.D., et al. (2003). The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. Journal of Investigative Dermatology, 120(3), 379–389.
7. Coffelt, S.B., et al. (2009). Elicited CD11b+Gr1+ myeloid cells inhibit LL-37-driven breast tumor cell invasion through the formation of neutrophil extracellular traps. Journal of Immunology, 183(10), 6538–6549.

See Also: Thymosin Alpha-1 Research · Dispersin B Research Overview · Biofilm Research Methods Overview